Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,506.48
(
-1.51%
)
US TECH 100
23,576.40
(
1.26%
)
Dow Jones
45,577.47
(
0.00%
)
Brent Oil
100.48
(
-7.08%
)
Bitcoin
70,280.30
(
3.59%
)
News Focus
News Focus
Post# of 257269
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

oc631

Send PM Follow Ignore
Followers 15
Posts 1749
Boards Moderated 0
Alias Born 08/12/2007

oc631

Re: None

Tuesday, 02/19/2013 9:51:47 AM

Tuesday, February 19, 2013 9:51:47 AM

Post# of 257269
GILD - FUSION GT2/GT3 results in treatment-experienced patients




http://finance.yahoo.com/news/gilead-sofosbuvir-hepatitis-c-meets-133000390.html



This is a double miss for my predictions. The SVR rate was 62% where I expected less than 50% after seeing 56% in treatment naives( @ 12-weeks). Also, and more importantly, 16-week data was better than 12-week which could bode well for other studies.
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today